10x Science, a Stanford lab spinout developing AI-native software for protein characterization, has raised $4.8M in seed funding led by Initialized Capital. The platform automates mass spectrometry data analysis, enabling 10x faster proteoform-resolved processing, peptide mapping, and de novo sequencing for biologics drug developers. The capital will accelerate platform development and expand to more pharma and biotech customers.
AI Discovery Outpaces Validation
The round arrives as AI generates protein drug candidates faster than labs can characterize them. Earendil Labs raised $787M in March 2026 for AI biologics design, while Eli Lilly inked a $2.8B deal with Insilico Medicine for AI-discovered drugs. 10x Science's vendor-agnostic AI addresses the downstream bottleneck in validating these candidates for clinical advancement.
Legacy Tools Lag Protein Complexity
Protein therapeutics require detailed molecular characterization, including post-translational modifications and proteoforms, yet manual expert analysis takes weeks. Legacy software from incumbents like Thermo Fisher Scientific and SCIEX struggles with terabyte-scale spectral data from modern mass specs. This gap slows biologics pipelines amid surging AI-driven discovery.
Deep Memory AI Automates Analysis
10x Science built an AI-native platform that processes mass spec data at the native binary level, using deep memory models that improve with customer datasets. It supports top-down, middle-down, and targeted proteomics workflows, delivering actionable insights in minutes rather than weeks. Unlike hardware-focused rivals like Portal Biotech or general proteomics tools from ProteoWise, 10x remains software-only and vendor-neutral.
As CEO David S. Roberts explained in TechCrunch:
"When biopharma tries to create a drug candidate, they have all of these really nice prediction tools… Everything needs to be measured."
Customer Matthew Crawford at Rilas Technologies added:
"I ran a particular protein through it, and it just kind of figured out… what the protein probably was."
Initialized Leads Biotech AI Bet
Y Combinator (W26 batch), Civilization Ventures—with exits like BillionToOne IPO—and angel syndicate Founder Factor joined Initialized. This mix signals conviction in AI infrastructure for biotech, mirroring YC's Benchling and Output Biosciences. Initialized partner Zoe Perret highlighted the SaaS model's recurring revenue potential for pharma.
Proteomics Market Scales with Biologics
The proteomics market stands at $45.7B in 2026, projected to reach $126.3B by 2035 at 13.2% CAGR, driven by biologics demand and AI integration. Trends like precision medicine amplify needs for rapid PTM analysis. 10x positions amid competitors like Inanovate (diagnostics-focused) and Atantares (chip-based), but leads in AI-native therapeutic workflows.
AI drug discovery floods pipelines, but characterization remains the choke point—10x Science unlocks faster iteration for pharma.
Nobel Lab Founders Drive Expertise
Founders hail from Carolyn Bertozzi's Stanford lab (2022 Chemistry Nobel winner), with CEO David Roberts boasting 37+ proteomics publications and 1500+ citations. CTO Vishnu Tejus brings AI scaling from Nooks (Series B), while COO Andrew Reiter adds Broad Institute MS experience and NSF fellowship. This domain depth directly tackles lived pains in protein analysis.
Early Traction Fuels Expansion
The platform is live with biopharma, biotech, and academic partners, including Rilas Technologies. Post-funding, 10x plans to hire a founding engineer to scale engineering amid growing customer demand.